Please login to the form below

Not currently logged in

Dr Reddy's enters deal with R-Pharm

India-based Dr Reddy's Laboratories has entered a licensing and development deal with Russian company R-Pharm

India-based Dr Reddy's Laboratories has entered a licensing and development deal with Russian company R-Pharm.

The agreement will see the companies, both based in leading emerging markets, co-develop high technology products and facilitate the sharing of knowledge. Manufacturing techniques will also be exchanged as part of the deal which will work on a profit sharing model.

With a focus on the development and marketing of generic medicines, Dr Reddy's has a global reach in key therapy areas. It first entered the Russian market in 1992.

R-Pharm is mainly focused on the R&D and manufacturing of new products, achieving total revenues of $15.3bn in 2009.

"We are excited about this collaboration as it helps us to deepen our engagement with Russia, one of our key markets," said Satish Reddy, managing director and chief operating officer, Dr. Reddy's. "The agreement allows us to bring innovative medicines to the Russian people with active collaboration of a local pharmaceutical company- RPharm. It will also allow Dr. Reddy's to import and market R-Pharm products in India according to agreed terms."

Alexey Repik, chairman of R-Pharm commented on the impact the deal would have on India-Russia relations: "This agreement helps address unmet medical needs in important therapeutic areas and make medicines more affordable to patients in Russia. It also pioneers a new way of collaboration between an Indian and a Russian pharmaceutical company. It is a change of approach from just imports of finished products to deep integration in technology, manufacturing, marketing and knowledge sharing."

The agreement follows plans announced by Denmark-based Novartis to invest $500m in the Russian pharmaceutical and healthcare industry, including the construction of a manufacturing plant in St Petersburg.

22nd December 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge